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Abstract
Background: Bifidobacteria and lactobacilli are among the early and important colonizers of the gastrointestinal
tract and are generally considered to be part of a normal, healthy microbiota. It is believed that specific strains
within the microbiota can influence host immune-reactivity and may play a role in protection from infection and
aberrant inflammatory activity. One such strain, Bifidobacterium animalis AHC7, has been previously shown to
protect against Salmonella typhimurium infection in mice and helps resolve acute idiopathic diarrhea in dogs. The
aim of this study was to investigate the potential molecular and cellular mechanisms underpinning the
Bifidobacterium animalis AHC7 protective effect.
Results: Following 4 hours of infection with Salmonella typhimurium, NF-B activation was significantly elevated in
vivo in placebo and Enterococcus faecium-fed animals while Bifidobacterium animalis AHC7 consumption
significantly attenuated the NF-B response. In vitro anti-CD3/CD28 stimulated Peyer’s patch cells secreted
significantly less TNF-a and IFN-g following Bifidobacterium animalis AHC7 consumption. Stimulated cells released
more IL-12p70 but this difference did not reach statistical significance. No alteration in mucosal IL-6, IL-10 or MCP-1
levels were observed. No statistically significant change in the cytokine profile of mesenteric lymph node cells was
noted. In vitro, Bifidobacterium animalis AHC7 was bound by dendritic cells and induced secretion of both IL-10
and IL-12p70. In addition, co-culture of CD4+ T cells with Bifidobacterium animalis AHC7-stimulated dendritic cells
resulted in a significant increase in CD25+Foxp3+ T cell numbers.
Conclusion: Bifidobacterium animalis AHC7 exerts an anti-inflammatory effect via the attenuation of pro-
inflammatory transcription factor activation in response to an infectious insult associated with modulation of pro-
inflammatory cytokine production within the mucosa. The cellular mechanism underpinning Bifidobacterium
animalis AHC7 mediated attenuation of NF-B activation may include recognition of the bacterium by dendritic
cells and induction of CD25+Foxp3+ T cells.
Background
It is becoming increasingly clear that the microbiota con-
dition and prime immunological function with an unex-
pected level of interdependence between bacteria and the
immune system [1]. Accumulating evidence suggests that
certain bacterial strains provide protective signals while
other bacterial strains stimulate aggressive and damaging
immune responses [2-5]. In other words, the activity of
the mammalian immune system seems to be governed by
the balance between symbiotic and potentially pathogenic
factors derived from our microbial inhabitants. This
raises the possibility that dysbiosis can lead to inap-
propriate inflammatory responses while on the other
hand certain well selected anti-inflammatory microbes
may protect against aberrant inflammatory activity.
The most important aspect of immunological function is
the ability to protect against infectious microbes. The host
response to infection requires innate and acquired cellular
and humoral immune reactions, designed to limit spread
of the offending organism and to restore organ homeosta-
sis [6]. However, to limit the aggressiveness of collateral
damage to host tissues, a range of regulatory constraints
may be activated, such as induction of T regulatory cells
[7]. A successful immune response is characterized by the
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efficient elimination of the pathogenic organism with
minimal inflammatory damage to the host and the asso-
ciated inflammatory cascades which may promote inflam-
matory disease. Innate pro-inflammatory signaling in
response to microbial exposure is mediated by the activa-
tion of transcription factors, such as NF-B, resulting in
expression of a battery of effector molecules contributing
to host defense and inflammation [8]. A number of bacter-
ial products have been identified which directly block acti-
vation of the NF-B pathway in epithelial cells via a range
of novel mechanisms including the blockade of I-B poly-
ubiquination by non-pathogenic Salmonella strains or the
enhancement of NF-B export from the nucleus by Bac-
teroides thetaiotaomicron [9,10]. In addition, non-patho-
genic microbes such as Bifidobacterium infantis 35624
have been demonstrated to limit excessive NF-B activa-
tion via the induction of T regulatory cells [11].
Interest in the deliberate administration of microbes, or
microbial metabolites, for the treatment of aberrant
inflammatory activity associated with an exuberant
immune response to pathogens is gaining momentum.
The typical microbes which are currently being examined
include Bifidobacteria, Lactobacilli, non-pathogenic E.
coli and Bacteroides strains [12-17]. The protective
effects associated with these microbes are probably
mediated by multiple mechanisms involving epithelial
cells, dendritic cells and T cells. One such organism, Bifi-
dobacterium animalis AHC7 (B. animalis AHC7), has
been previously shown to protect against Salmonella
typhimurium infection in murine models and helps
resolve acute diarrhea in dogs [18,19]. However, the host
immunological molecular events contributing to this pro-
tective mechanism have not been described. Therefore,
we have examined activation of the pro-inflammatory
transcription factor NF-B in animals pretreated with B.
animalis AHC7 or E. faecium SF68. E. faecium SF68 has
been previously described as a probiotic organism with
immunomodulatory activity and we used this bacterial
strain as a comparator microbe for B. animalis AHC7
[20,21]. In addition, we have examined the influence of B.
animalis AHC7 on dendritic cell activation and T cell
polarization. Our data suggests that the B. animalis
AHC7 protective effect is associated with modulation of
NF-B activity in vivo while in vitro studies demonstrate
that dendritic cell recognition of this bacterium is asso-
ciated with induction of CD25+Foxp3+ T cells.
Results
B. animalis AHC7 suppresses NF-B activation in vivo
Infection of mice with S. typhimurium results in potent
activation of NF-B systemically after 4 hours (Figure
1a). Representative animals were dissected and indivi-
dual organs re-imaged for localisation of in vivo NF-B
activity (Figure 1b). Isolated ileum displayed specific
areas of activation which macroscopically co-localized
with Peyer’s patches. Within the colon, a different pat-
tern was observed with a single foci of high activity
associated with a lower level of activation at the
???
??????????????????????????????????? ????? ????????
?????????????????
??????????
Figure 1 Biophotonic imaging of S. typhimurium induced NF-B activation. Following 4 hours of infection with S. typhimurium in mice fed
control diets, whole body biophotonic imaging revealed a significant increase in NF-B activation. Two representative animals are illustrated (a).
Isolated gastrointestinal tissue from S. typhimurium-infected animals displays enhanced NF-B activation within the ileum and colon (b). Isolated
spleen and liver tissue also display NF-kB activity following S. typhimurium infection (c). The region of interest (ROI) is shown with the photons/
sec/cm2 value for representative ROI included.
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proximal and distal segments. Isolated spleen and liver
also displayed elevated NF-B activity following 4 hours
of S. typhimurium infection. Placebo-fed animals dis-
played a significant up-regulation of NF-B whole body
activity after 4 hours infection (Figure 2). Pre-feeding
with B. animalis AHC7 significantly attenuated the acti-
vation of this pro-inflammatory transcription factor. In
order to determine if the attenuation of NF-B activity
was bacterium-strain specific, additional mice were
pre-fed E. faecium prior to S. typhimurium infection.
Up-regulation of NF-B activity was similar in the pla-
cebo-fed animals and E. faecium-fed animals (Figure 2).
B. animalis AHC7 mucosal immunoregulatory activity
In order to determine if lymphocytes within the mucosa
could be influenced by B. animalis AHC7 consumption,
healthy mice were administered the bacterial strain or
placebo for 3 weeks. Peyer’s patch lymphocytes displayed
an altered cytokine secretion profile following in vitro sti-
mulation. Anti-CD3/CD28 antibody stimulation of
Peyer’s patch cells from B. animalis AHC7 fed animals
secreted significant lower levels of IFN-g and TNF-a
(Figure 3a). In contrast, secretion of IL-10 was unaltered
while IL-12p70 levels were increased (p = 0.07) compared
to placebo-fed animals (Figure 3b). No differences were
noted for IL-6 or MCP-1 levels (data not shown) or for
the un-stimulated cultures. In addition, no alteration in
anti-CD3/CD28 stimulated mesenteric lymph node
secretion of IL-6, IL-10, IL-12p70, TNF-a, IFN-g or
MCP-1 was observed for B. animalis AHC7-fed animals
compared to placebo-fed controls (data not shown).
B. animalis AHC7 interaction with dendritic cells
Human monocyte derived dendritic cells (MDDCs) were
co-incubated with CFSE-labelled B. animalis AHC7
in vitro and imaged for evidence of bacterial binding.
*
Figure 2 B. animalis AHC7 attenuates S. typhimurium induced NF-B activation. Mice consumed placebo, B. animalis AHC7 or E. faecium for
3 weeks prior to S. typhimurium infection. Biophotonic imaging was performed on all animals at time 0 and 4 hours following infection. The
increase in bioluminescence (i.e. NF-B activation) from baseline (time 0) to 4 hours is illustrated for each group. *p < 0.05 versus placebo
(n = 10 animals per group).
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CFSE labeled B. animalis AHC7 was easily visualized on
the cell surface of CD11c+ MDDCs indicating efficient
binding of this bacterium by human myeloid dendritic
cells (Figure 4). In addition, MDDCs secreted IL-10 and
IL-12p70 in response to B. animalis AHC7 (Figure 5).
Indeed, IL-10 secretion in response to this microbe was
significantly greater than the MDDC response to LPS
while the level of IL-12p70 secretion was equivalent to
that induced by LPS.
B. animalis AHC7 conditioned dendritic cells influence
T cell polarisation
Following co-incubation with B. animalis AHC7 for
4 hours, MDDCs were extensively washed and co-incubated
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Figure 3 Peyer’s patch cytokine secretion. Isolated Peyer’s patch cells were cultured in vitro with or without anti-CD3/CD28 stimulation.
Secretion of TNF-a and IFN-g was significantly reduced in animals pre-fed B. animalis AHC7 (a). Secretion of IL-10 was unaltered between the
groups while a non-statistically significant increase in IL-12 secretion was observed (b). *p < 0.05 versus placebo (n = 10 animals per group).
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with autologous CD4+ T cells for 5 days. T cells were re-
stimulated with anti-CD3/CD28 antibodies for 2 days and
transcription factor levels quantified by flow cytometry. B.
animalis AHC7-stimulated MDDCs induced significantly
more CD25+Foxp3+ T cells compared to non-stimulated
MDDCs or LPS stimulated MDDCs (Figure 6).
Discussion
This report illustrates, at a cellular and molecular level,
the impact of the commensal microbiota on host
immune defense and immune homeostasis. The deliber-
ate consumption of one commensal organism, B. ani-
malis AHC7, resulted in the attenuation of NF-B
activation within mice infected with a pro-inflammatory
translocating microbe, S. typhimurium. In addition, B.
animalis AHC7 consumption was associated with mod-
ulation of cytokine signaling within the mucosa of
healthy animals. In vitro, dendritic cells bound B. ani-
malis AHC7, secreted IL-10 and IL-12p70, and dendritic
cells stimulated with B. animalis AHC7 enhanced Foxp3
expression in naïve T cells.
Infection by microbes such as Salmonella species results
in severe immunopathology characterized by loss of intest-
inal barrier function, tissue cell death and loss of function,
fever and ultimately can lead to death of the host [22].
The pathology is not only a direct effect of the microbe
itself but is a consequence of the inflammatory response
induced by the presence of the organism. Therefore Sal-
monella infection of mice is a good model system to
examine the regulatory mechanisms which protect against
excessive pro-inflammatory responses to a range of pro-
inflammatory stimuli and not only Salmonella itself. The
resident microbiota can aid in the protection against aber-
rant inflammatory activity as suggested by studies in
germ-free mice where infection with S. typhimurium
results in colitis which was not observed in conventionally
colonized animals [23]. In addition, specific commensal
organisms such as B. animalis AHC7 protect against S.
typhimurium infection and disease severity [19]. While B.
animalis AHC7 may directly antagonize Salmonella
within the gastrointestinal tract, this is unlikely to be the
primary mechanism as other commensal organisms which
were significantly more effective than B. animalis AHC7
at killing S. typhimurium in vitro, did not protect against
infection in vivo [19]. These studies suggest that the biolo-
gical activity of certain commensal microbes is exerted
well beyond a direct influence on the microbiota within
the gastrointestinal tract. Therefore, we investigated
whether B. animalis AHC7 could exert an effect on the
host via regulation of the pro-inflammatory response as a
potential mechanism underpinning its protective effect.
S. typhimurium infects the host via intestinal epithelial
cells and dendritic cells. In addition, Salmonella infects
via M cells which transport the bacterium to underlying
Peyer’s patches for immunological processing [24]. Infec-
tion of the Peyer’s patches leads to recruitment of a large
number of pro-inflammatory infiltrating leukocytes
which further aggravate intestinal inflammation and pro-
mote systemic dissemination of the pathogen. B. animalis
AHC7 consumption leads to an altered cytokine profile
within Peyer’s patches which may protect against exces-
sive inflammation. Release of TNF-a and IFN-g by stimu-
lated Peyer’s patch lymphocytes in vitro is significantly
reduced. In contrast, release of the Th1 cytokine IL-12 is
enhanced with no alteration in IL-6, IL-10 or MCP-1
levels. Interpretation of these results is complex as IFN-g
and IL-12 are both considered to be Th1 cytokines. IL-
12p70 is released by cells of the innate immune system,
such as dendritic cells, while IFN-g is secreted by T cells
suggesting that B. animalis AHC7 consumption may dif-
ferentially regulate dendritic cell and T cell cytokine pro-
duction. In vitro, B. animalis stimulated dendritic cells
secrete IL-12 and therefore the increased IL-12 release by
Peyer’s patch cells may be dendritic cell derived. Regard-
less of the mechanism, it is clear that in vitro stimulated
cytokine responses from Peyer’s patch cells are modu-
lated by B. animalis AHC7 consumption and it is likely
that these altered responses contribute to the anti-
inflammatory effect observed in the Salmonella model. In
particular, reduced secretion of TNF-a, which is a key
pro-inflammatory cytokine, would reduce the inflamma-
tory burden following S. typhimurium infection.
Innate immune activation to Salmonella is mediated
via pattern recognition receptors, such as TLR-5, which
rapidly up-regulate NF-B activity [25]. Both mucosal
and systemic NF-B activation in response to Salmo-
nella infection was noted suggesting that widespread
activation of the innate immune system occurs rapidly
and this response is modulated by B. animalis AHC7
consumption. The molecular basis for this inhibitory
activity is not known and may involve induction of sup-
pressor molecules, induction of regulatory cells (such as
Tregs), down-regulation of TLR expression and/or activ-
ity and enhancement of the mucosal immunological bar-
rier. Previously we have shown that increased numbers
of CD25+Foxp3+ T cells can reduce NF-B activation
in vivo [11]. We did not assess CD25+Foxp3+ T cell
polarization in B. animalis AHC7- fed animals but the
in vitro co-culture model using B. animalis conditioned
dendritic cells clearly demonstrated that this bacterium
can induce a dendritic cell response which induces
CD25+Foxp3+ T cells. However, it remains to be deter-
mined if this mechanism is responsible for the B. ani-
malis AHC7 anti-inflammatory effect in vivo.
Conclusion
NF-B is a key pro-inflammatory transcription factor
and improved regulation of NF-B is an important
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therapeutic target in a wide range of pro-inflammatory
states, including sepsis [26]. This report supports the
clinical evaluation of appropriately selected probiotic/
commensal micro-organisms, such as B. animalis
AHC7, for the promotion of regulatory mechanisms in
vivo which limit aberrant pro-inflammatory activity.
However, it is clear from this study and others that not
all commensal microbes modulate host immunological
activity in the same way and the defining features of
potent anti-inflammatory microbes remain to be
described.
Methods
Bacterial strains
B. animalis AHC7 was routinely cultured anaerobically
for 48 hours in deMann, Ragosa and Sharpe medium,
MRS (Oxoid, Basingstoke, UK) supplemented with
0.05% cysteine (Sigma, Dublin, Ireland). Enterococcus
?
CD11c+                         CFSE+                     Merged 
Figure 4 Dendritic Cells Bind B. animalis AHC7. Representative pictures are shown which illustrate binding of CFSE-labeled B. animalis AHC7
(green) to CD11c+ monocyte derived dendritic cells (red).
*
Figure 5 Dendritic Cells Secrete IL-10 and IL-12p70 in Response to B. animalis AHC7. MDDCs co-incubated with B. animalis AHC7 or LPS
for 24 hours secrete significant levels of IL-10 and IL-12p70. Results represent the mean of three independent experiments. *p < 0.05 versus LPS-
stimulated MDDCs.
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faecium SF68 was routinely cultured aerobically at 37°C
for 24 hours in on tryptic soya broth, TSB (Oxoid).
Freeze-dried powders of these strains were generated for
use in subsequent animal studies. Salmonella typhimur-
ium UK1 was generously provided by Prof. Roy Curtiss
III (Washington University, USA) and was routinely cul-
tured aerobically at 37°C for 24 hours in TSB (Oxoid).
Murine studies
NF-Blux transgenic mice on a Balb/c background were
obtained from Charles River Laboratories (MA, USA)
and bred in-house for salmonella infection studies. Mice
were housed under barrier maintained conditions within
the biological services unit, University College Cork
(UCC). All animal experiments were approved by the
UCC animal ethics committee and experimental proce-
dures were conducted under appropriate license from
the Irish government. Female NF-Blux mice were admi-
nistered freeze-dried B. animalis AHC7 or E. faecium
SF68 in their water supply at approximately 5 × 108
CFU/day or cryoprotectant carrier (n = 10 per group)
for 3 weeks prior to a single oral challenge with 1 × 107
S. typhimurium. NF-B activation was visualized at time
0 and 4 hours following infection using the protocol as
previously described [11,27]. Briefly, D-luciferin (120
mg/kg; Biothema AB, Handen, Sweden) was injected i.p.
and immediately anaesthetized mice were placed in a
ventral recumbent position in an In Vivo Imaging Sys-
tem (IVIS) chamber (Xenogen, Alameda, USA) and
imaged continuously for 5 minutes with a medium sen-
sitivity setting starting 2 minutes after the injection of
D-luciferin. Photons were quantified using Living Image
software (Xenogen) and the luciferase activity quantified
as the amount of light emitted per second per cm2 from
the animal. Following imaging, all mice were humanely
euthanized.
Wild-type Balb/c mice were obtained from Harlan
(Oxon, UK) and bred in-house for bifidobacterial feed-
ing. Female Balb/c mice (n = 8 per group) received
either freeze-dried B. animalis AHC7 or placebo (cryo-
protectant carrier) administered on a daily basis in their
drinking water. Each animal received an approximate
dose of 5 × 108 CFU/day. Drinking water bottles were
changed every day with fresh probiotic freeze-dried
powders as previously described [19,28]. After 3 weeks
of treatment the mice were humanely euthanized fol-
lowed by isolation of Peyer’s patches and mesenteric
lymph nodes.
In vitro Culture of Mucosal Cells
Single cell suspensions from Peyer’s patches or mesen-
teric lymph nodes from Balb/c mice were cultured in
vitro for 48 hours with anti-CD3/anti-CD28 antibodies
(BD Biosciences, Oxford, UK) or remained non-stimu-
lated. Supernatants were harvested for cytokine analysis
and stored at -80°C until quantification by multiplex
profiling. IL-6, TNF-a, IL-10, IL-12p70, IFN-g and
MCP-1 cytokine levels were quantified using cytometric
bead arrays (BD).
Dendritic Cell Isolation and Culture
Human CD14+ monocytes were isolated from peripheral
blood using antibody labeling and magnetic separation
(Miltenyi, Gladbach, Germany) and cultured in the pre-
sence of IL-4 (200 ng/ml, gift from Novartis, Basel, Swit-
zerland) and GM-CSF (1,000 Units/ml, Peprotech,
???????? ?????? ???????? ??????? ???????? ????????
?? ?? ???
??
??
?????
?
Figure 6 B. animalis AHC7 stimulated MDDCs induce CD25+Foxp3+ T Cells. Following co-incubation with MDDCs, CD4+ T cells were
stained for CD25 and Foxp3. B. animalis AHC7 stimulated MDDCs induced more CD25+Foxp3+ T cells than LPS stimulated or non-stimulated
MDDCs. Representative results from three independent experiments are illustrated.
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Hamburg, Germany) for 5 days to generate CD11c+
monocyte derived dendritic cells (MDDCs). 5 × 105
MDDCs were incubated with 1 × 107 B. animalis AHC7
labeled with carboxyfluorescein succinimidyl ester
(CFSE, Invitrogen, Carlsbad, USA). After two hours
incubation, MDDCs were stained with anti-human
CD11c-PE-Cy5 (BD) and cells were visualized using the
Image Stream X system (Amnis Corporation, Seattle,
USA) and analyzed with IDEAS software (Amnis Cor-
poration). In addition, non-CFSE stained B. animalis
AHC7, or LPS (Sigma), were used to stimulate MDDCs
for 24 hours and cytokine levels in the culture superna-
tants were measured by the multiplex Luminex platform.
MDDC-T Cell Co-Culture
MDDCs were isolated as above and autologous CD4+ T
cells were isolated using antibody binding and magnetic
separation (Miltenyi). MDDCs were stimulated with B.
animalis AHC7, LPS or remained non-stimulated for
four hours and washed four times to remove un-bound
bacteria. MDDCs were co-incubated with autologous
CD4+ T cells for five days (1:20 ratio) in FCS-free med-
ium followed by re-stimulation with anti-CD3/CD28
antibodies for two days. Flow cytometric quantification
of CD4+CD25+Foxp3+ T cells (all antibodies from
eBioscience, Frankfurt, Germany) was performed on a
Gallios flow cytometer (Beckman Coulter) and the data
was analysed using Kaluza software (Beckman Coulter).
Statistics
Two way-ANOVA with Bonferroni’s Post-test was used
to determine statistical significance between treatment
groups for NF-B activation. The differences in cytokine
levels between groups was evaluated using a Mann-
Whitney t-test. All data were expressed as arithmetic
mean±SEM. The level of statistically significance was set
at p < 0.05. All statistical evaluations were performed
using the statistical software package GraphPad Prism
4.03 (GraphPad Software, Inc., San Diego, CA, USA).
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